• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, July 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Upsalite® inhibits bacteria without penicillin

Bioengineer by Bioengineer
November 18, 2016
in Science News
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

(Uppsala University) The mesoporous material Upsalite® is shown to inhibit growth of bacteria associated with acne and hospital acquired infections. In a study published in ACS Omega, researchers at Uppsala University have shown that the mesoporous magnesium carbonate Upsalite® exerts strong bacteriostatic effect on Staphylococcus epidermidis.

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Delayed vs Early Cord Clamping in Preterm Twins: Echocardiography Study

Delayed vs Early Cord Clamping in Preterm Twins: Echocardiography Study

July 18, 2026
Omics and AI in Pediatric Environmental Health: Tools, Challenges, Cohort Insights

Omics and AI in Pediatric Environmental Health: Tools, Challenges, Cohort Insights

July 18, 2026

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

July 18, 2026

Necrotizing Enterocolitis: A Paradigm Shift in Understanding

July 18, 2026
Please login to join discussion

POPULAR NEWS

  • A painless adhesive

    49 shares
    Share 20 Tweet 12
  • Groundbreaking Discovery: New Shark Species Identified for the First Time

    34 shares
    Share 14 Tweet 9
  • 研究人员开发认知工具包,实现阿尔茨海默症早期检测

    50 shares
    Share 20 Tweet 13
  • A varied menu

    51 shares
    Share 22 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Delayed vs Early Cord Clamping in Preterm Twins: Echocardiography Study

Omics and AI in Pediatric Environmental Health: Tools, Challenges, Cohort Insights

Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.